Rxsight Inc
NASDAQ:RXST
Net Margin
Rxsight Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Rxsight Inc
NASDAQ:RXST
|
352.3m USD |
-22%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
6.6T JPY |
23%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
32.9B CHF |
11%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
138.8B DKK |
15%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
10.5B USD |
11%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.5B CHF |
12%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5B GBP |
9%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
47.3B CNY |
40%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5.3B USD |
8%
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.3B USD |
-6%
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
700.5B JPY |
9%
|
Rxsight Inc
Glance View
In the dynamic realm of ophthalmology, RxSight Inc. has carved a niche as a pioneering force in enhancing vision outcomes for cataract patients. At the heart of the company’s innovation is its Light Adjustable Lens (LAL) system. Traditional intraocular lenses (IOLs), once implanted, lock patients into a certain prescription, accepting only minimal adjustments. RxSight, with its groundbreaking technology, offers a solution that breaks this convention. Post-cataract surgery, the LAL allows ophthalmologists to precisely adjust the lens prescription using UV light, often yielding better visual acuity tailored to patient needs. This transformative approach turns the one-size-fits-all model of vision correction into a personalized patient experience, promising a brighter, clearer outlook on life. Commercially, RxSight operates within the medical device industry, focusing on capturing a significant share of the cataract surgery market—one of the most frequent surgeries performed worldwide. The company earns revenue primarily through the sale of its LAL system to eye care professionals and clinics. This business model is akin to a razor-and-blade approach; besides the initial sale of the adjustable lenses, RxSight garners continuous revenue from associated products and services, such as the light delivery device and follow-up adjustments required post-surgery. By addressing a substantial unmet need with a recurring revenue stream, RxSight strategically positions itself for growth within the burgeoning biotech sector, all while setting new benchmarks for patient satisfaction in eye care.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Rxsight Inc's most recent financial statements, the company has Net Margin of -21.9%.
You don't have any saved screeners yet